Pharmaceutical Solutions

All Drugs and Chemicals

Vorolanib

Protein Kinase Inhibitors

Enzyme Inhibitors

Subjects will be administered with one single dose of CM082 tablet (test product) under fasted state, after a wash period of 5 days, the subjects will be administered with one single dose of CM082 tablet (reference product) under fasted state.

Subjects will be administered with one single dose of CM082 tablet (reference product) under fasted state, after a wash period of 5 days,the subjects will be administered with one single dose of CM082 tablet (test product) under fasted state.

Subjects will be administered with one single dose of CM082 tablet (test product) after meal, after a wash period of 5 days,the subjects will be administered with one single dose of CM082 tablet (reference product) after meal.

Subjects will be administered with one single dose of CM082 tablet (reference product) after meal, after a wash period of 14 days,the subjects will be administered with one single dose of CM082 tablet (test product) after meal

Test product(T)：100mg CM082 tablet manufactured by Betta Pharmaceuticals

CM082 tablet (test product)

Reference product(R)：100mg CM082 tablet manufactured by Catalent Pharma Solutions

CM082 tablet (reference product)

zourong ruan

The main objective of this study is to evaluate the bioequivalency of two preparations of CM082 tablet in Chinese healthy volunteers.

The main objective of this study is to evaluate the bioequivalency of two preparations of CM082 tablet in Chinese healthy volunteers under fasted state or after meal. In addition, the safety of single dose administration of CM082 tablet in Chinese healthy volunteers will also be evaluated.

Bioequivalency Study of CM082 Tablet in Healthy Volunteers

Randomized,Open Label,Two-cycle,Crossover,Single Dose Bioequivalency Study of Two Preparations of CM082 Tablet in Healthy Chinese Volunteers Under Fasted State and After Meal

The Cmax ofCM082 (test product or reference product) in under fasted state or after meal blood samples of each subject over a 72 hour period post dose

The AUC of CM082 (test product or reference product) in under fasted state or after meal blood samples of each subject over a 72 hour period post dose

The Tmax of CM082 (test product or reference product) in under fasted state or after meal blood samples of each subject over a 72 hour period post dose

Percentage of adverse events as assessed by CTCAE v4.03

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Bioequivalency Study of CM082 Tablet in Healthy Volunteers	NCT04328506	Advanced Malign...	CM082 tablet (t... CM082 tablet (r...	18 Years - 45 Years	AnewPharma
Bioequivalency Study of CM082 Tablet in Healthy Volunteers	NCT04328506	Advanced Malign...	CM082 tablet (t... CM082 tablet (r...	18 Years - 45 Years	AnewPharma

Spots Global Cancer Trial Database for cm082 tablet (test product)